EP Patent

EP4504202B1 — Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Assigned to Genentech Inc · Expires 2026-02-04 · 0y expired

What this patent protects

Patent listed against Inrebic.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

Patent Metadata

Patent number: EP4504202B1
Jurisdiction: EP
Classification: —
Expires: 2026-02-04
Drug substance claim: No
Drug product claim: No
Assignee: Genentech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.